EpCAM is highly and frequently expressed in the vast majority of carcinomas, in tumor-initiating cells, and in disseminated tumor cells, which qualified EpCAM as a potential target for cancer therapies [15, 91, 92]. The gene discussed is EPCAM; the disease is neoplasm.